<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308968</url>
  </required_header>
  <id_info>
    <org_study_id>TV48125-CNS-30068</org_study_id>
    <secondary_id>2017-002441-30</secondary_id>
    <nct_id>NCT03308968</nct_id>
  </id_info>
  <brief_title>An Efficacy and Safety Study of Fremanezumab in Adults With Migraine</brief_title>
  <acronym>FOCUS</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Study With an Open-Label Period to Evaluate the Efficacy and Safety of Fremanezumab for the Prophylactic Treatment of Migraine in Patients With Inadequate Response to Prior Preventive Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of monthly
      and quarterly subcutaneous (sc) injections of fremanezumab compared with sc injections of
      placebo in patients with chronic migraine (CM) or episodic migraine (EM) who have responded
      inadequately to 2 to 4 classes of prior preventive treatments.

      Approximately equal numbers of patients from each subgroup (CM and EM) are randomized in
      blinded-fashion 1:1:1 into one of three treatments for the subgroup - two active treatments
      and one placebo treatment --- consisting of monthly injections for 3 months (up to week 12).
      Then all participants continue into an open-label extension of 3 months (weeks 13-week 24)
      during which everyone is administered sc injections of fremanezumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2017</start_date>
  <completion_date type="Anticipated">August 27, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 22, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change from baseline in the monthly average number of migraine days during the double-blind period</measure>
    <time_frame>Baseline (days -28 to 0), Treatment up to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients reaching at least 50% reduction in the monthly average number of migraine days during the double-blind period</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in the monthly average number of headache days of at least moderate severity during the double-blind period</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in the monthly average number of migraine days during the double-blind period</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>proportion of patients reaching at least 50% reduction in the monthly average number of migraine days during the double-blind period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in the monthly average number of days of use of any acute headache medications during the double-blind period</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change from baseline in the number of headache days of at least moderate severity during the double-blind period</measure>
    <time_frame>Baseline, 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients who did not complete study due to AEs</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">804</enrollment>
  <condition>Migraine Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Fremanezumab Monthly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the double-blind period, participants with chronic migraine (CM) are administered Dosage A subcutaneous (sc) injection of fremanezumab at Week 0 (baseline) followed by Dosage B sc injections at Week 4 and Week 8 and participants with episodic migraine (EM) are administered Dosage B subcutaneous (sc) injection of fremanezumab at Week 0 (baseline), Week 4, and Week 8 then followed by an open label period where all participants are administered Dosage B sc injection of fremanezumab at Weeks 12, 16 and 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fremanezumab Quarterly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the double-blind period, participants with chronic migraine (CM) and participants with episodic migraine (EM) are administered Dosage A sc injection of fremanezumab at Week 0 (baseline) followed by placebo sc injections at Week 4 and Week 8 followed by an open label period where all participants are administered Dosage B sc injection of fremanezumab at Weeks 12, 16 and 20.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>During the double-blind period, participants with chronic migraine (CM) and participants with episodic migraine (EM) are administered 3 placebo sc injections at Week 0, and 1 placebo injection at weeks 4 and 8 followed by an open label period where all participants are administered Dosage B sc injection of fremanezumab at Weeks 12, 16 and 20.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fremanezumab</intervention_name>
    <description>Prefilled syringes contain Dosage B total of active ingredient fremanezumab administered by subcutaneous injection. Week 0 doses of Dosage A consisted of three injections. Week 0 doses of Dosage B consisted of one injection.</description>
    <arm_group_label>Fremanezumab Monthly</arm_group_label>
    <arm_group_label>Fremanezumab Quarterly</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>TEV-48125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Prefilled syringes contain the same vehicle as the active intervention administered by subcutaneous injection. Week 0 doses of Dosage B consisted of two injections of placebo to maintain the blind. Week 0 doses of placebo consisted of three injections of placebo to maintain the blind.</description>
    <arm_group_label>Fremanezumab Quarterly</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a diagnosis of migraine with onset at ≤50 years of age.

          -  Body weight ≥45 kg

          -  The patient has a history of migraine for ≥12 months prior to screening.

          -  Women of childbearing potential (WOCBP) whose male partners are potentially fertile
             (ie, no vasectomy) must use highly effective birth control methods for the duration of
             the study and the follow-up period and for 6.0 months after discontinuation of
             investigational medicinal product (IMP)

          -  Men must be sterile, or if they are potentially fertile/reproductively competent (not
             surgically [eg, vasectomy] or congenitally sterile) and their female partners are of
             childbearing potential, must use, together with their female partners, acceptable
             birth control methods for the duration of the study and for 6.0 months after
             discontinuation of the investigational medicinal product (IMP).

               -  Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  At the time of screening visit, patient is receiving any preventive migraine
             medications, regardless of the medical indication for more than 5 days and expects to
             continue with these medications.

          -  Patient has received onabotulinumtoxinA for migraine or for any medical or cosmetic
             reasons requiring injections in the head, face, or neck during the 3 months before
             screening visit.

          -  The patient has used an intervention/device (eg, scheduled nerve blocks and
             transcranial magnetic stimulation) for migraine during the 2 months prior to
             screening.

          -  The patient uses triptans/ergots as preventive therapies for migraine.

          -  Patient uses non-steroidal anti-inflammatory drugs (NSAIDs) as preventive therapy for
             migraine on nearly daily basis for other indications. Note: Low dose aspirin (eg, 81
             mg) used for cardiovascular disease prevention is allowed.

               -  Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teva U.S Medical Information</last_name>
    <phone>1-888-483-8279</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Investigational Site 14742</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-329-0197</phone>
      <email>ssharp@cranashville.com; ssharp@clinicalresearchassociates.com; ssharp@cranashville.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14729</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-799-7799</phone>
      <email>omidomidvar@cnstrial.com; annie@btheodore.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14739</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 857 496-0054 (557)</phone>
      <email>vmehra@artemis-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14843</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>310-315-1456</phone>
      <email>dbkudrow@earthlink.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14749</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80918</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>719-262-9283</phone>
      <email>kroberson@deltawaves.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14762</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>352-333-0094</phone>
      <email>drj@ehsfamily.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14758</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-426-9299</phone>
      <email>eheurich@meridienresearch.net; drheurich@compassresearch.coml;eheurich@compassresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14738</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>407-425-5100</phone>
      <email>rmolpus@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14760</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>404-537-1281</phone>
      <email>drjohnson@iresearchatlanta.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14737</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1-208-377-8653 (105)</phone>
      <email>mturnerpharmaresearch@gmail.com; mturner@acr-research.com; mturnerpharmaresearch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14730</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>312-431-6780</phone>
      <email>dsugimoto@cedarcrosse.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14740</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>847-869-1192</phone>
      <email>jgeohas@evanstonpremier.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14735</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>501-224-1348</phone>
      <email>goodbrain@aol.com; research@bhccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14747</name>
      <address>
        <city>Pikesville</city>
        <state>Maryland</state>
        <zip>21208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 (857) 496-0054 (557)</phone>
      <email>rlehman@pharmasiteresearch.com; riley@clin-edge.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14750</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-799-7799</phone>
      <email>omidomidvar@cnstrial.com; annie@btheodore.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14734</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-636-5848</phone>
      <email>spierings@medvadis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14731</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>734-677-6000</phone>
      <email>jrs@mhni.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14748</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>612-333-2200</phone>
      <email>gdb@allergy-asthma-docs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14746</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>402-934-0044</phone>
      <email>dunn@qcromaha.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14754</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>856-753-7335</phone>
      <email>drmhassman@hritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14752</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>505-224-7407</phone>
      <email>msalazar@abqct.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14753</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>716-250-2000</phone>
      <email>lmechtler@dentinstitute.com; lmechtle@buffalo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14736</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>336-574-8000</phone>
      <email>mfreeman212@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14741</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>336-574-8020</phone>
      <email>rvonseggern@pharmquest.biz; pharmquest@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14732</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>919-781-2514</phone>
      <email>sjagadeesan@wakeresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14756</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>401-739-3573</phone>
      <email>dr.fried@omegamedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14745</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>901-843-1045</phone>
      <email>lmcgill@cnshealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14743</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>615-284-4680</phone>
      <email>jbrandes1@msn.com; jbrandes@nashvilleneuroscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14733</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1-512-380-9925 (214)</phone>
      <email>jdh@sleepdoc.net;jdh@fstrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14751</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1-801-542-8190 (116)</phone>
      <email>jkirstein@acr-research.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37092</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 5045 2370</phone>
      <email>annelies.vandycke@azsintjan.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37089</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 2477 6410</phone>
      <email>jan.versijpt@uzbrussel.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37091</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 1 133 7880</phone>
      <email>nina.deklippel@jessazh.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 37090</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 4321 7811</phone>
      <email>delphine.magis@chrcitadelle.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54162</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420 734 574 598</phone>
      <email>nadezda.fiserova@ccbr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54165</name>
      <address>
        <city>Ostrava-Moravska</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+42-057-600-0232</phone>
      <email>zahumenska@seznam.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54159</name>
      <address>
        <city>Ostrava</city>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+42 555 508 685</phone>
      <email>martin.piperek@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54158</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420 464 629 121</phone>
      <email>tomas.hala@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54164</name>
      <address>
        <city>Prague 4</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420-261-082-416</phone>
      <email>jolana.markova@ftn.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54163</name>
      <address>
        <city>Prague</city>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420 222 510 607</phone>
      <email>y.rizova@clintrial.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54160</name>
      <address>
        <city>Praha 10</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+42-060-816-4394</phone>
      <email>mbajacek@yahoo.co.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54161</name>
      <address>
        <city>Praha 3</city>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420-23-023-0940</phone>
      <email>martina.machkova@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54166</name>
      <address>
        <city>Praha 8</city>
        <zip>186 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+42 223 002 222</phone>
      <email>nezadal@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 54157</name>
      <address>
        <city>Rychnov nad Kneznou</city>
        <zip>51601</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+420 491 112 720</phone>
      <email>pazdera@vestraclinics.org; pazdera@neurol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 39051</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+45 9633 4709</phone>
      <email>anna.areovimata@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 39049</name>
      <address>
        <city>Arhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+45 78 462 080</phone>
      <email>flemming.bach@rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 39052</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+45-44-704-470</phone>
      <email>ulla.schmidt@ccbr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 39048</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+45 386 338 39</phone>
      <email>messoud.ashina@regionh.dk; ashina@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 39050</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+45 757 260 74</phone>
      <email>annette.justesen@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40034</name>
      <address>
        <city>Helsinki</city>
        <zip>00100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>petra.keski-santti@terveystalo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40035</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+358-50-555-2977</phone>
      <email>markus.farkkila@fimnet.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40036</name>
      <address>
        <city>Oulu</city>
        <zip>90100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+358 407 592 939</phone>
      <email>mikko.karppa@oulu.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40033</name>
      <address>
        <city>Tampere</city>
        <zip>FI-33100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>﻿﻿+35 84 0587 4149</phone>
      <email>memasu@uta.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40032</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+35-840-078-8020</phone>
      <email>markku.nissila@terveystalo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 40037</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+35 84 0530 9775</phone>
      <email>juha-pekka.eralinna@neuroneo.fi</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35237</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 721 188 66</phone>
      <email>genevieve.demarquay@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35238</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 3 204 46 642</phone>
      <email>christian.lucas@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35235</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 91 38 43 45</phone>
      <email>anne.donnet@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35240</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+33 4 92 03 79 46</phone>
      <email>lanteri-minet.m@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35239</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mirela.muresan@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 35236</name>
      <address>
        <city>Voiron</city>
        <zip>38500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+32 4 766 77 534</phone>
      <email>gerard.mick@ch-voiron.fr;secretariat-mick@ch-voiron.fr, gerard.mick@ch-voiron.fr, ge.mick@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32697</name>
      <address>
        <city>Berlin</city>
        <zip>10177</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 30 450 560 274</phone>
      <email>uwe.reuter@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32690</name>
      <address>
        <city>Berlin</city>
        <zip>D-10435</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 304 434 1901</phone>
      <email>jansen@schmerzzentrum-berlin.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32694</name>
      <address>
        <city>Bochum</city>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 234 158 66</phone>
      <email>philipp@stude.de; philipp.stude@bergmannsheil.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32699</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49-201-436-9624</phone>
      <email>hans.diener@uk-eshans.diener@uni-duisburg-essen.de; h.diener@uni-essen.de;kontakt@ms-center-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32692</name>
      <address>
        <city>Goppingen</city>
        <zip>73033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49-7161-976-45</phone>
      <email>gerhard@mueller-schwefe.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32691</name>
      <address>
        <city>Halle</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 345 557 2858</phone>
      <email>torsten.kraya@medizin.uni-halle.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32698</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 407 410 59 189</phone>
      <email>a.may@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32700</name>
      <address>
        <city>Kiel</city>
        <zip>24149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49-431-200-99-100</phone>
      <email>hg@schmerzklinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32695</name>
      <address>
        <city>Konigstein im Taunus</city>
        <zip>61462</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 617 429 040</phone>
      <email>c.gaul@migraene-klinik.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32689</name>
      <address>
        <city>Muenchen</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+49-89-440-073-900</phone>
      <email>andreas.straube@med.uni-muenchen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32701</name>
      <address>
        <city>Rostock</city>
        <zip>18147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 381 494 4768</phone>
      <email>tim.juergens@med.uni-rostock.de; t.juergens@uke.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 32693</name>
      <address>
        <city>Ulm</city>
        <zip>89073</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 731 602 80 440</phone>
      <email>cepek@neurologie-ulm.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30203</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39-512-902-929</phone>
      <email>pietro.cortelli@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30199</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+39 55 275 8202</phone>
      <email>pierangelo.geppetti@unifi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30201</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 5 942 24 211</phone>
      <email>centrocefalee@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30202</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 382 380 425</phone>
      <email>cristina.tassorelli@mondino.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30204</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 062 254 11220</phone>
      <email>f.vernieri@unicampus.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30198</name>
      <address>
        <city>Rome</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39 6 337 75 111</phone>
      <email>paolo.martelletti@uniroma1.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 30200</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+39-01-131-35-770</phone>
      <email>chiara.benedetto@unito.it; chbened@tin.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38126</name>
      <address>
        <city>Amsterdam</city>
        <zip>1078VV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31 2 030 50 051</phone>
      <email>emilecouturier@me.com; neuroboerhaave@me.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38127</name>
      <address>
        <city>Blaricum</city>
        <zip>1261 AN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+31 8 875 312 501 258</phone>
      <email>pbouma@tergooi.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38124</name>
      <address>
        <city>Leiden</city>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+31 71 526 2895</phone>
      <email>m.d.ferrari@lumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 38125</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>g.schoonman@etz.nl; polineuro@etz.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53420</name>
      <address>
        <city>Krakow</city>
        <zip>31-209</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 122 941 616</phone>
      <email>epilepsy@vp.pl; clpim@poczta.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53425</name>
      <address>
        <city>Krakow</city>
        <zip>33-332</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 126 563 141</phone>
      <email>martabanach@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53422</name>
      <address>
        <city>Lodz</city>
        <zip>90-338</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 514 415 154</phone>
      <email>jacek.rozniecki@umed.lodz.pl; jjrozniecki@afazja.am.lodz.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53424</name>
      <address>
        <city>Lodz</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 60 171 6573</phone>
      <email>piotr.pelczar@ccbr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53418</name>
      <address>
        <city>Lublin</city>
        <zip>20-022</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48-815-327-177</phone>
      <email>aszerej@poczta.onet.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53416</name>
      <address>
        <city>Poznan</city>
        <zip>60-529</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 61 831 2710</phone>
      <email>olgierd_stefanski@interia.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53419</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48-918-136-322</phone>
      <email>marcin.ratajczak@euromedis.pl; marcin.ratajczak@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53417</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+48-22-681-64-46</phone>
      <email>astepien@wim.mil.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 53423</name>
      <address>
        <city>Warszawa</city>
        <zip>04-730</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+48 226 816 446</phone>
      <email>zanna.pastuszak@bioclinica.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31231</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 902 444 446</phone>
      <email>ppozo@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31235</name>
      <address>
        <city>Madrid</city>
        <zip>28223</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 630 347 021</phone>
      <email>japareja@fhalcorcon.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31236</name>
      <address>
        <city>Madrid</city>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ger.latorre@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31226</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34-948-255-400</phone>
      <email>pirimia@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31229</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+34 942 202 655</phone>
      <email>agustin.oterino@hotmail.com; aoterino@humv.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31230</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 981 951 086</phone>
      <email>rogelio.leira@usc.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31234</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 955 923 000</phone>
      <email>mjimenez@us.es; carmengoria@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31233</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 963 607 644</phone>
      <email>miguel.lainez@sen.es; jlaineza@meditex.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31227</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34-96-124-4000</phone>
      <email>sdiazinsa@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31225</name>
      <address>
        <city>Valladolid</city>
        <zip>47003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34-983-420-000</phone>
      <email>gueneurol@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 31228</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+34 976 768 873</phone>
      <email>ssantos@salud.aragon.es; ssantosl@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42050</name>
      <address>
        <city>Helsingborg</city>
        <zip>252 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 42 13 53 53</phone>
      <email>johan.neuro@telia.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42049</name>
      <address>
        <city>Huddinge</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 8 585 80 000</phone>
      <email>ingela.nilsson-remahl@sll.se; ingela.nilsson-remahl@karolinska.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42051</name>
      <address>
        <city>Lund</city>
        <zip>260 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 722 277 701</phone>
      <email>ulf@neurologen.se; ulf@frejvall.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42052</name>
      <address>
        <city>Stockholm</city>
        <zip>112 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 86 18 08 31</phone>
      <email>prefer_phonecalls@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 42054</name>
      <address>
        <city>Stockholm</city>
        <zip>114 33</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+46 812 45 80 00</phone>
      <email>tor.ansved@neuroclinic.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 45018</name>
      <address>
        <city>Bad Zurzach</city>
        <zip>5330</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+41 56 269 5151</phone>
      <email>a.gantenbein@rehaclinic.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 45016</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+41 31 632 6361</phone>
      <email>christoph.schankin@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 45017</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+41 09 1811 6221</phone>
      <email>chiara.zecca@eoc.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34231</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 1 41 232 7542</phone>
      <email>aloktyagi@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34232</name>
      <address>
        <city>Hull</city>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 148 267 5591</phone>
      <email>fayyaz.ahmed@hey.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34229</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7LJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+44 151 529 5666</phone>
      <email>nicholas.silver@thewaltoncentre.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34233</name>
      <address>
        <city>London</city>
        <zip>SE5 9NT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 20 329 96 384</phone>
      <email>peter.goadsby@kcl.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34230</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>+44 186 523 1894</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34235</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 191 256 3331</phone>
      <email>adam.zermansky@srft.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 34236</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 178 267 9455</phone>
      <email>brendan.davies@uhnm.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2017</study_first_submitted>
  <study_first_submitted_qc>October 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 13, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

